RetaMaps

Lite Medical Clinic PLLC - Richfield Bloomington

Lite Medical Clinic PLLC - Richfield Bloomington · 6414 Nicollet Avenue · Richfield, MN 55423

5.0· 57 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

About this practice

Lite Medical Clinic's Richfield office, listed with Bloomington, offers hormone therapy and medical weight loss in Richfield, Minnesota, per the practice's website, which describes a seven-location Minnesota group founded by Dr. Kyle Kingsley, MD. The site describes a whole-body approach, and telehealth visits are available at this location. Google shows a 5.0-star rating across 57 reviews, beginning in 2024, with 38 in the past year. Reviewers mention the staff most often (19 reviews), followed by the providers' knowledge, and seven reviews mention results.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsYes
Cash pay acceptedYes
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 5.0
Google rating · 57 reviews
38
reviews in the past year (avg ★ 5.0)
6
reviews mention weight loss

Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-18. Read the reviews themselves on the practice's Google listing.

What patients say

This practice holds a ★5.0 Google rating across 57 reviews. 98% of the 57 reviews we analyzed are 5-star. reviewers most often mention staff & front desk (19), professionalism & expertise (11), results (7), feeling listened to (4).

5★
56
4★
1
3★
0
2★
0
1★
0

Most recent Google reviews

Dawa D.★★★★★2026-09-18

Richfield and Eden Prairie locations are so accommodating and hardworking!

Jennifer B.★★★★★2026-08-21

I went to the Richfield location today and received such great information and care. I can’t wait to start this journey with the help of Lite Medical!

Mary M.★★★★★2026-08-11

I had a great first time experience. My nurse practitioner Annabeth made me feel totally at ease and explained everything in detail. She was lovely. No judgement, just total support.

Margarett D.★★★★★2026-08-04

I will recommend this clinic as they have been so upfront, concerned about my care, my questions are always answered. Very professional at all times.

Brittany W.★★★★★2026-06-03

Love the Nicollet location! All the staff is knowledgeable, professional and supportive! Highly recommend!!!

Reviews and counts are from this practice's public Google Business listing and reflect their authors' opinions, not RetaMaps'. See all reviews on Google.

Nearby providers in Richfield

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs